Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Kelly C. Goldsmith(Emory University), Yaël P. Mossé(Children's Hospital of Philadelphia), Holger Thurm(Pfizer (United States)), John M. Maris(Children's Hospital of Philadelphia), Hiroyuki Shimada(National Center for Geriatrics and Gerontology), Patricia T. Acharya(University of Southern California), Esther R. Berko(Children's Hospital of Philadelphia), Rajen Mody(University of Michigan), Julie R. Park(Seattle Children's Hospital), Katherine K. Matthay(University of California System), Araz Marachelian(University of Southern California), Daniel A. Morgenstern(University of Toronto), Marlon Liyanage(Pfizer (United States)), Ami V. Desai(University of Chicago Medical Center), Meaghan Granger(Cook Children's Medical Center), Kateryna Krytska(Children's Hospital of Philadelphia), Fariba Goodarzian(University of the West of Scotland), Jemily Malvar(University of Southern California), Margaret E. Macy(Children's Hospital Colorado), Bruce Pawel(University of Southern California), Louis Chesler(Institute of Cancer Research), Lillian M. Lai(University of Iowa Hospitals and Clinics), Susan Groshen(USC Norris Comprehensive Cancer Center), Yueh‐Yun Chi(University of Southern California), Kieuhoa T. Vo(UCSF Benioff Children's Hospital), Gudrun Schleiermacher(Inserm), Suzanne Shusterman(Dana-Farber Cancer Institute), Lisa J. States(Children's Hospital of Philadelphia), Gerson Peltz(Tennessee Oncology), Judith G. Villablanca(University of Southern California), Navin Pinto(Seattle Children's Hospital), Lynley V. Marshall(Royal Marsden Hospital), Joseph Chen(Pfizer (United States)), Kimberly Kayser(Vanderbilt University Medical Center), Susan Ghazarian(Children's Hospital of Los Angeles)
Cited by 125
Related Papers
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
|New England Journal of Medicine|2005|571